Requests for Applications released for MGNet Scholar and Pilot Grant programs; see also updates on the Explore MG 2 and ADAPT-TeleMG studies.

Challenges in conducting clinical research in the midst of the COVID-19 pandemic are spotlighted in an article from three consortia of the Rare Diseases Clinical Research Network (RDCRN).

MGNet announces 2021 Pilot Grant awardees, and provides updates on the Scholar Program, Organizational Meeting, and Scientific Symposium, and offers insight into studies including Explore MG2, ADAPT-teleMG, Biomarker Discovery for MG, and MuSK MG Study.

Announcing the 2021 MGNet Scholar along with updates on the Clinical Outcome Measures Symposium and Pilot Program.

Consortium updates regarding the Scholar Program, Pilot Program, and the Explore MG2 and Adapt Tele-MG Studies.

2020 MGNet Pilot Award recipient announced, exploring a virtual pilot study amid COVID-19, recapping the first virtual industry symposium.

The Myasthenia Gravis Rare Disease Network (MGNet) has awarded the 2020 MGNet Pilot Award to Carolina Barnett-Tapia, MD, PhD, Assistant Professor, Department of Medicine (Neurology) and Institute of Health Policy, Management and Evaluation, University of Toronto. Dr. Barnett-Tapia specializes in patient-centered outcomes in neuromuscular disorders, researching patients’ perspectives on their symptoms and treatments.

The Myasthenia Gravis Rare Disease Network (MGNet) has awarded the 2020 MGNet Scholar Award to Amanda Guidon, MD, a neuromuscular neurologist at the Massachusetts General Hospital and an assistant professor of neurology at Harvard Medical School.

2020 MGNet Scholar Award Recipient, MGNet Virtual Symposium, and the COVID-19 Webinar.

A webinar on myasthenia gravis featuring Hana Axelrod, MD, MPH and Henry J. Kaminski, MD, of MGNet talk about COVID-19 and its impacts on myasthenia gravis patients.

The National Institutes of Health (NIH) awarded a research team at the George Washington University (GW) $7.8 million to establish a rare disease network for myasthenia gravis. The network, which will become one of 23 established NIH Rare Diseases Clinical Research Networks, will include basic and clinical investigators, patient advocacy groups, and biotechnology and pharmaceutical companies working together to enhance therapeutic development for this rare disease.